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Malaria, historically one of the greatest
causes of human misery and death1–3, is
today relatively contained outside of
Africa. This is being achieved with in-
secticides to attack the mosquito vectors
and by treating human infections with
anti-malarial drugs. However, partly through the emergence
and spread of resistance by the parasites and their vectors to
these chemically based methods of control, this containment
is being steadily eroded. The problem is exacerbated by
concerns for the environment stemming from the use of in-
secticides such as DDT (refs. 4,5). Therefore, alternative ap-
proaches to malaria control 
are urgently needed. Malaria
vaccines have long been the
subject of intensive research,
and although they have yet to
be realized clinically, they are 
at least now becoming a techni-
cal possibility6–8.
In the second part of the last
century, vaccines against infec-
tious diseases proved very
effective. Successful vaccination
campaigns against polio, yellow
fever, small pox, measles and so
on not only protected the vacci-
nated individuals against infec-
tion but also protected others in
the community by reducing the
further spread of the infection.
Likewise, malaria vaccines are
being developed to achieve both
protection of the vaccinated in-
dividual and the reduction of
malaria transmission through
the community.
However, for the malaria para-
site, the stages that cause disease
are different from the stages that
transmit the parasites from the
mosquito vector to the human
host and vice versa. Accordingly,
vaccines are being developed
against the different parasite
stages to achieve these different
effects (Fig. 1). Liver-stage vac-
cines will reduce the chance of a
person becoming sick. Asexual
blood-stage vaccines will reduce disease
severity and risk of death during infec-
tion. Vaccines against stages that infect
mosquitoes will directly prevent the
spread of malaria through the commu-
nity. It is this last group that are known
as malaria transmission-blocking vaccines9 (TBVs).
One of the main problems confronting malaria vaccine de-
velopment in general is the relatively low level of commercial
interest. This is because the potential market with endemic
malaria is mainly in the poorest countries who despite their
medical need, do not have the economic means to support
large-scale purchase and distribu-
tion. In fact, industry’s greatest
interest is in liver- and blood-
stage vaccines, which are being
designed to target travelers and
the military entering malaria-en-
demic regions from the wealthy
and mostly malaria-free regions
of the world. Unfortunately, it is
proving almost impossible to
stimulate commercial develop-
ment of TBVs whose use would
be restricted to poor, malaria-en-
demic countries.
TBVs prevent the transmission
of malaria by inducing antibodies
against antigens present on the
sexual stages of the parasites,
which develop in the mosquito
midgut, and thus block their de-
velopment in the mosquito.
Candidate formulations at or ap-
proaching a grade suitable for
testing as human TBVs are now
available (D. Kaslow and C. Long,
personal communication) (Table
1 & 2). Research-grade formula-
tions of TBV candidates have
been shown to induce antibodies
that completely block transmis-
sion to mosquitoes of the two
principal human malaria para-
sites, P. falciparum and P. vivax9
(H. Hisaeda et al., personal com-
munication).
Although, motivated by the
public health relevance of the
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Fig. 1 Different stages of the malaria parasite life cycle against
which vaccines are being developed.
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transmission-blocking effects of vaccination against malaria,
the scientific community and its funders have made much
progress towards the technical development of this type of
malaria vaccine9, TBV development has proceeded slowly,
mainly because of the lack of a committed industrial partner. It
is timely, therefore, to ask how essential TBVs would really be
for malaria control, and, if they were developed, how this could
be achieved.
A meeting* to discuss these issues included representatives
from the pharmaceutical industry and major funding agencies,
scientific experts with detailed knowledge and experience in
the technical aspects of malaria vaccine development and re-
gional representatives and experts in malaria epidemiology and
in medical ethics. This meeting’s purpose was to achieve an au-
thoritative statement on the issues concerning malaria TBVs
(ref. 10).
Central to the discussions was the practical value of TBV as a
tool for reducing the burden of malaria. There has been much
skepticism and some confusion about this, (including in this
journal; see ref. 11 and Letters, p. 234) with some people imply-
ing that malaria transmission rates must be reduced to zero to
remove malaria from a particular environment. The same con-
fusion has led many malaria experts to reject Ronald Ross’ (cor-
rect) claim12 that below a certain transmission rate, that of a
basic reproduction number10 equal to 1, malaria cannot be sus-
tained. Such perceptions, that malaria TBVs would have little
effect, have fed the lack of commercial interest in their devel-
opment. The meeting gave in-depth consideration to the po-
tential effect of TBVs and reached the following main
conclusions.
In most malaria-endemic locations, TBV coverage, even if
partial, would reduce disease and death due to malaria. In areas
of relatively low transmission, as in most endemic locations
outside tropical Africa, and also possibly in parts of tropical
Africa itself, malarial disease would be reduced probably in di-
rect proportion to the effective coverage with TBVs. In many
situations of low malaria endemicity, transmission could be
stopped by TBVs. In some more highly endemic areas, the de-
ployment of TBVs in conjunction with more traditional mea-
sures such as insecticide-impregnated bed nets could bring the
end of malaria transmission within reach. Even incomplete
TBV coverage would slow the build-up of malaria epidemics
and reduce their size very substantially in many situations13.
Because of the limited dispersal range of the mosquito vec-
tors of malaria (a few hundred meters to a kilometer), individ-
ual communities composed of stable and settled human
Table 1 Properties and current state of product development of leading malaria transmission-blocking vaccine candidates
Antigen Strengths Weaknesses Current state of development
Pfs25 and Antibodies against Not expressed in the human host P. vivax and P. falciparum
Pvs25 Pfs25 or Pvs25 can completely and so not subject to genes both cloned and expressed.
block transmission of P. falciparum natural boosting by malarial 
or P. vivax to mosquitoes. infection following vaccination. Vaccination with both the P.vivax
and P. falciparum yeast-expressed 
In most areas where TBV would be Because immunity to these vaccines  clones induces complete 
used both P. falciparum and will probably not be boosted by transmission-blocking
P. vivax are endemic. natural infection, formulations to in model systems.
Therefore, it is very prolong the immune response to 
important that both Pfs25 vaccination may need to be developed. Clinical grade yeast-expressed 
and Pvs25 are being developed  Pfs25 produced.
to be used together in the Parasites can still infect mosquitoes
same vaccine. when the gene for these proteins Clinical grade yeast-expressed 
has been knocked out. Pvs25 soon to be produced.
Pfs28 and Similar to Pfs25 and Pvs25. Similar to Pfs25 and Pvs28. Similar to Pfs25 and Pvs25 
Pvs28 but clinical grade 
material being planned.
Pfs25 + Pfs28 Parasites cannot infect Not expressed in the human host See above.
and Pvs25 mosquitoes if both 25 and so not subject to natural 
+ Pvs28 and 28 genes are knocked out. boosting by malarial infection
Therefore, there is advantage to following vaccination.
combining the 25 and 28  
molecules in the same vaccine Because immunity to these vaccines
because, while the parasites can will probably not be boosted
evade immunity against either by natural infection, formulations 
one by deleting its gene, to prolong the immune 
they cannot survive the response to vaccination
deletion of both genes. may need to be developed.
Immunization with both 25 and 
28 may be synergistic in inducing 
transmission blocking antibodies.
* Transmission Blocking Malaria Vaccines: and the Ideal Public Sector Enterprise. United Nations Development Programme/World Bank/World Health Organization Special Programme
for Research and Training in Tropical Diseases (TDR) and the Roll Back Malaria projects of the World Health Organization, the US National Institutes of Health and The Bill and Melinda
Gates Foundation, Bethesda, Maryland, 3–5 December 1999.

































NATURE MEDICINE • VOLUME 6 • NUMBER 3 • MARCH 2000 243
COMMENTARY
populations could probably be protected from malaria by
small, local TBV vaccination campaigns. The idea that a TBV
program requires the vaccination of individuals who will not
themselves benefit has often been raised as an ethical objection
to TBVs. However, for the same reason that the vectors of
malaria have limited dispersal, it follows that within a vacci-
nated household the household members themselves, usually
members of the same family, and their immediate neighbors
will tend to be the main beneficiaries of such vaccination. The
ethical nature of TBV in this context was a view endorsed by
representatives from the endemic countries.
One further important property of TBVs is that they would
reduce the emergence and spread of parasites resistant to other
malaria vaccine components, and even to anti-malarial drugs.
In this respect, the use of TBVs could substantially prolong the
effective life of other malaria vaccine components and possibly
also of anti-malarial drugs.
At the technical level, much progress has been made in iden-
tifying suitable target antigens for TBV against both of the
main species of human malaria, P. falciparum and P. vivax
(Table 1 & 2). These antigens are surface proteins of the extra-
cellular sexual stages of the parasites—gametes and zygotes—in
the midgut of a blood-fed mosquito9 (Fig. 1c). Moreover, the
immune mechanism of transmission-blocking immunity
against these antigens is known (antibody-mediated blockade
of the development of the parasites in the mosquito). This has
enabled an ex vivo assay (gametocyte-infected blood fed to mos-
quitoes through an artificial membrane in the presence of
serum from an immunized subject) to be used as a realistic test
for malaria transmission-blocking immunity. Using this assay,
the immunogenicity of a TBV construct can be tested in human
volunteers without requiring the infection of each volunteer
with malaria. This is an enormous advantage in the develop-
ment of a human vaccine. Immunogenic constructs represent-
ing zygote surface antigens of both the main human malaria
parasites P. falciparum and P. vivax have been produced in yeast
and have passed through the early stages of TBV trials using the
assay described above.
A problem specifically associated with the current leading
candidate antigens for TBVs is that they will probably not be
boosted by malarial infection (Table 1 & 2). This is because
these antigens, the Pfs25 and Pfs28 zygote surface proteins of P.
falciparum (and their equivalents for P. vivax), are expressed
only after fertilization in the mosquito midgut and are not pre-
sent in the gametocytes as they circulate in the blood. Thus, a
vaccinated community could be at risk of an epidemic return of
malaria once their vaccine-induced transmission-blocking im-
munity has waned. Therefore, formulations may need to be de-
veloped to extend the effective life of TBV-induced immunity. 
Difficulties in the deployment of TBVs are likely to arise in
achieving optimum levels of coverage, as adults as well as in-
fants and children will need to be vaccinated. There would be a
real challenge in explaining the concept of a vaccine that pre-
vents the spread of infection without conferring direct protec-
tion upon the individual. It is to be hoped, however, that the
transmission-blocking components of a malaria vaccine would
be used in formulations that included components for the di-
rect protection of the vaccinated individual against malarial in-
fection. In any event, malaria vaccination campaigns will have
to be part of an integrated program of malaria control in which
educational, health and vector-control services work together.
In this context, most of the difficulties described here could be
overcome.
Therefore, the consensus of the meeting was that TBVs
Table 2 Properties and current state of product development of leading malaria transmission-blocking vaccine candidates
Antigen Strengths Weaknesses Current State of Development
Pfs48/45 Antibodies to Pfs48/45 Difficulty in expressing P. falciparum gene cloned.
can completely block  recombinant products 
transmission of P. falciparum in immunogenic form. Protein expressed in E. coli 




infection in the human host;
probable boosting of transmission-
blocking antibody 
response during an infection.
Essential for 
fertilization in gene 
knock-out experiments.
Pfs230 Antibodies to Pfs230 Very large molecule; P. falciparum gene cloned.
can completely difficult to determine 
block transmission which regions would be Fragments have been 
of P. falciparum effective in a vaccine. expressed as E. coli
to mosquitoes. MBP-fusion proteins; 
induce some 
Expressed on the transmission-blocking activity.
gametocyte during the
infection in the human host; Fragments have been
probable boosting of expressed in yeast; induce 
transmission-blocking some transmission-blocking 
antibody response during an infection. activity.
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would be very valuable tools against malaria and that their pro-
duction is technically feasible. Moreover, the effects of a TBV
would be complementary and even synergistic in combination
with other malaria vaccine components and control measures.
Given the present lack of industrial interest in a malaria TBV,
the problem remains of how to fund and manage the large-
scale developmental research and the human trials of candi-
date TBVs. The situation calls for a substantial public sector
intervention. In response to this, the Bethesda meeting pro-
posed the formation of a consortium of interested parties and a
secretariat to plan and manage the development of a malaria
TBVs. Its mission would include the coordination of TBV re-
search and development, the mobilization of funds for these
operations, and negotiations with other organizations, such as
governments of countries where trials would take place, whose
involvement would be necessary to reach the goal.
Thus, scientists from laboratories around the world have 
declared an interest and a commitment to the development of
malaria TBVs and have proposed a mechanism through which
this might be achieved. The question now is: Who will support
and finance such a venture?
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